ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Case Report

    Ursu HI, Hortopan D, Podia-Igna C, Vizireanu A, Harsan T, Dumitriu L, Alexandrescu D

    Late onset Graves thyrotoxicosis in a patient with 18 years history of euthyroid Graves ophtalmopathy

    Acta Endo (Buc) 2005 1(2): 227-232 doi: 10.4183/aeb.2005.227

    Abstract References
    A 38 years old, heavy smoker, was admitted in our thyroid unit in August 1993 with left eye proptosis (21 mm), right eye prosthesis and euthyroidism. Orbital CT scan revealed inferior rectus muscle hypertrophy in the left orbit and possible residual (postoperative) lateral rectus muscle hypertrophy in the right orbit. Left eye proptosis was treated with both glucocorticoids and orbital radiotherapy.\r\nSeven years before (1986) the patient developed right eye proptosis, without clinical features of hyperthyroidism. Being suspected of a sphenoid ring meningioma and since orbital CT scan was not available at that time, a right orbit exploration was performed in November 1987; soon after orbital exploration, clinical features suggesting right orbital cellulitis occurred, followed by right eye evisceration and right eye prosthesis. After 18 years of Graves ophthalmopathy with euthyroidism, in February 2004 an autoimmune hyperthyroidism was diagnosed (suppressed TSH, high TT3, positive TRAb), being successfully treated with radioiodine. One year after the ablative therapy the patient is still euthyroid. A patient with euthyroid Graves ophthalmopathy should be monitored indefinitely, since a thyroid dysfunction may occur even after more than a decade.
    1. Bahn RS, Heufelder AE. Pathogenesis of Graves ophthalmopathy. N Engl J Med 1993; 329(20): 1468 - 1475.
    2. Gerding NM, Terwee CB, Dekker FW, Koornneef L , Prummel MF, Wiersinga WM. Quality of life in patients with Graves ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument.Thyroid 1997; 7(6): 885 - 889. [CrossRef]
    3. Bahn RS. Pathophysiology of Graves ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003; 88(5): 1939 - 1946. [CrossRef]
    4. Wiersinga WM. Preventing Graves ophthalmopathy. N Engl J Med 1998; 338(2): 121 - 122. [CrossRef]
    5. Burch HB, Wartofsky L. Graves ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14(6): 747 - 793.
    6. Dallow RL. Evaluation of unilateral exophthalmos with ultrasonography: analysis of 258 consecutive cases. Laryngoscope 1975; 85(11): 1905 - 1919. [CrossRef]
    7. Bartalena L, Marcocci C, Tanda ML et al. Cigarette smoking and treatment outcome in Graves ophthalmopathy. Ann Intern Med 1998; 129(8): 633 - 635.
    8. Bartalena L, Marcocci C, Pinchera A. Graves ophthalmopathy: a preventable disease? Eur J Endocrinol 2002; 146(4): 457 - 461. [CrossRef]
    9. Barnes PJ, Karin M. Nuclear Factor - kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066 - 1071.
    10. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orb [CrossRef]
    11. Weissel M, Hauff W. Fatal liver failure after high dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10(6): 521.
    12. Martino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves ophthalmopathy. Thyroid 2004; 14(5): 403 - 406. [CrossRef]
    13. Gorman CA. Temporal relationship between onset of Graves ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 1983; 58(8): 515 - 519.
    14. Ursu H, Hortopan D, Alexandrescu D, Coculescu M. An unusual side effect of glucocorticoid therapy in Graves ophthalmopathy. Romanian Journal of Endocrinology and Metabolism 2004; 3(4): 75 - 78.
    15. Brokken LJS, Wiersinga WM, Prummel MF. Thyrotropin receptor antibodies are associated with continued thyrotropin suppression in treated euthyroid Graves disease patients. J Clin Endocrinol Metab 2003; 88(9): 4135 - 4138. [CrossRef]
  • Endocrine Care

    Ursuleanu A, Nicodin O, Gussi I, Niculescu N, Costachescu G

    Triptorelin Modulation of Gonadal Steroidogenesis as a Preoperative Treatment in Leiomyomata Uteri

    Acta Endo (Buc) 2012 8(2): 231-238 doi: 10.4183/aeb.2012.231

    Abstract
    Introduction. The gold standard for surgery of fibroids is vaginal surgery and a preoperative treatment that facilitates this approach through reduction of the uterine\r\nvolume is of utmost importance. GnRH agonists and selective progesterone receptor modulators (SPRM) have both been tested to this effect.\r\nObjective. To evaluate whether uterine shrinkage induced by preoperative GnRH agonists in women with uteruses > 280g may\r\nfacilitate vaginal hysterectomy (VH).\r\nMaterial and methods. 23 women scheduled to have an abdominal hysterectomy based on the uterine size over 280 g were allocated to receive the GnRH agonist triptorelin 3.75 mg monthly for three months. Uterine weight (estimated by ultrasound), serum levels of estradiol and Hb were assessed before treatment and monthly afterwards three times.\r\nResults. Estradiol levels decreased from 235.9?15 to 38?3.7pg/mL at three months (p<0.0001), after an initial flare up. Hb increased from 11.85?1.8 to 12.7?0.74 g/dL.\r\nThe uterine weight decreased from 443.5?39 to 294.8?31 g (by 33.5%), all patients benefitting from a VH.\r\nConclusion. In women with a large uterus impending an abdominal hysterectomy, a 3-month preoperative course of GnRH agonists facilitates VH by decreasing uterine size by 30%.
  • Case Report

    Datcu MD, Datcu G, Fermesanu I, Aursulesei V

    Pheochromocytoma &#8211; late diagnosis after subarachnoid haemorrhage

    Acta Endo (Buc) 2009 5(2): 265-274 doi: 10.4183/aeb.2009.265

    Abstract
    Background: Despite a low incidence and prevalence, pheochromocytoma requires a\r\nparticular attention when evaluating hypertensive patients. If undiagnosed, the excessive\r\nand prolonged secretion of catecholamines may cause considerable cardiovascular\r\nmorbidity and mortality. The wide variability of clinical manifestations makes the diagnosis\r\ndifficult, and biochemical confirmation of the disease is mandatory.\r\nCase report: a 32-year-old patient, admitted to hospital with acute left ventricular\r\nfailure caused by severe arterial hypertension associated with the clinical triad (headaches +\r\npalpitations + sweating). The debut of the disease was manifested with a subarachnoid\r\nhaemorrhage. The aetiology remains unclear in the absence of confirmed arterial\r\nhypertension antecedents. In subsequent months he had paroxysmal rhythm abnormalities\r\nassociated with ECG signs of left ventricular hypertrophy considered to be due to nonobstructive\r\nhypertrophic cardiomyopathy. For a period of further three years the patient was\r\nrepeatedly hospitalized for paroxystic elevations of blood pressure not responding to\r\nantihypertensive medication. He developed diabetes mellitus and was started on insulintherapy.\r\nDuring the recent hospitalization, the diagnosis of pheochromocytoma was\r\nconsidered in view of clinical history and the severe hypertension-induced organ damage.\r\nThe diagnosis was confirmed biochemically and a right adrenal tumour was demonstrated\r\non CT. After a successful open adrenalectomy his hypertension was cured.\r\nIn conclusion, the case presented highlights the importance of recognising the symptoms\r\nand clinical signs suggestive of PHEO in order to reach a correct and timely diagnosis.
  • General Endocrinology

    Cakmak Genc G, Karakas Celik S, Arpaci D, Aktas T, Can M, Bayraktaroglu T, Dursun A

    Granulysin Peptide and Gene Polymorphism in the Pathogenesis of Hashimoto Thyroiditis

    Acta Endo (Buc) 2022 18(3): 288-293 doi: 10.4183/aeb.2022/288

    Abstract
    Background. Hashimoto thyroiditis (HT) is an autoimmune disease and the most common cause of hypothyroidism. The widespread lymphocyte infiltration in the thyroid gland and intolerance of the body against its thyroid antigens leads to the destruction of thyroid cells and impaired thyroid function. Granulysin (GNLY) is a cytolytic antimicrobial peptide that has been associated with a wide range of diseases such as various infections, cancer, transplantation, and skin problems. However, there are a few studies investigating the relationship between HT and granulysin. Aim. Our study aims to investigate whether granulysin levels and GNLY gene polymorphism contribute to the damaged immune response leading to HT. Material and Methods. 100 unrelated patients diagnosed with HT and 140 healthy individuals were included in our study. Frequencies of GNLY rs10180391 and rs7908 gene polymorphisms were determined using PCR- RFLP method and serum granulysin levels were determined using ELISA. Results. There is no statistical significance between patient and control groups in terms of genotype and allele frequencies of GNLY gene polymorphisms and serum levels of granulysin. Conclusion. In conclusion, granulysin and GNLY gene polymorphisms do not appear to relate to HT disease.
  • Actualities in medicine

    Ursu HI

    Actualities in Thyroidology

    Acta Endo (Buc) 2014 10(2): 309-311 doi: 10.4183/aeb.2014.309

  • Endocrine Care

    Gussi I, Ursuleanu A, Ceausu I, Dutescu C, Lazar V, Mirciulescu C

    Longer Duration and Lower Fatal Risk of Late-onset Pregnancy-related Ovarian Hyperstimulation Syndrome

    Acta Endo (Buc) 2011 7(3): 357-363 doi: 10.4183/aeb.2011.357

    Abstract
    Background. Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of the luteal\r\nphase or early pregnancy after ovulation induction or ovarian stimulation. The late OHSS form presents an onset more than 10 days after ovulation triggering and is\r\ninfluenced by pregnancy-related HCG secretion.\r\nReport. This paper presents three cases of pregnancy-related OHSS after IVF/ICSI cycles discussing risk factors and management according to European Guidelines.\r\nResults. Individual risk factors are identified such as low BMI, high antral follicle count at the beginning of the ovarian stimulation, high estradiol over 3000 pg/ml.\r\nPatients had moderate OHSS (case 2) and severe OHSS (case 1 and 3). In-patient treatment was 3-14 days. OHSS resolved in\r\nall cases, without manifestations of the critical form.\r\nConclusion. The duration of OHSS is longer in the late form, is pregnancy-related and should be monitored for adverse\r\npregnancy outcomes. However the incidence of fatal risks is low and the treatment is successful.
  • General Endocrinology

    Purice M, Ursu IH, Baicus C, Goldstein A, Niculescu DA

    Hyperhomocysteinemia in moderate and severe hypothyroidism

    Acta Endo (Buc) 2010 6(4): 431-442 doi: 10.4183/aeb.2010.431

    Abstract
    The aim of the study was to evaluate the prevalence of hyperhomocysteinemia in hypothyroid patients and the effect of folic acid supplementation when serum homocysteine\r\n(Hcy) was over risk level.\r\nPatients and methods. Patients with moderate (Group1) and severe hypothyroidism (Group 2) were evaluated before any therapy and after 6 months of combined folic acid and\r\nlevothyroxine substitution, versus control subjects. Hcy, folic acid, thyroid hormones and lipids were measured for all subjects. Thyroglobulin and antithyroglobulin antibodies were measured only for Group 2.\r\nResults. Only 17 % of the cases had basal Hcy at non risk level (<10 mmol/L). Both groups had higher Hcy levels than control (p <0.0001). In Group 1 basal folic acid was lower\r\nthan in control and group 2 (p<0.001). No correlation was found between high levels of Hcy (> 12 mmol/L ) and positive thyroglobulin. After 3 months of combined therapy, significant decrease of Hcy (p<0.0001) was observed compared with the basal level. Normalization of\r\nHcy appears during next 3 months even with reducing the folic acid supplementation.\r\nConclusion. Our results report moderate hyperhomocysteinemia in hypothyroid patients. This may exacerbate the cardiovascular risk traditionally attributed to lipid changes. Six months of combined therapy (L-thyroxine and folic acid) corrected hyperhomocysteinemia excluding the additional risk.
  • Editorial

    Ursu H, Badiu C, Gheorghiu ML

    Selenium, Mild Graves Ophthalmopathy and Current Smoking Status

    Acta Endo (Buc) 2012 8(3): 467-470 doi: 10.4183/aeb.2012.467

  • Case Report

    Ursu HI, Purice M, Belgun M, Suciu I, Ioan D

    Down syndrome and Turner syndrome associated with Graves' disease: two case reports and a review of the literature

    Acta Endo (Buc) 2008 4(4): 471-476 doi: 10.4183/aeb.2008.471

    Abstract
    About 15-20% of adults with Down?s syndrome have autoimmune hypothyroidism. Among patients with Down?s syndrome, prevalence of Graves disease (1-2%) may not be increased compared with the general population. About 15% of the patients with Turner?s syndrome have autoimmune hypothyroidism. Until 2006, only 15 cases of Graves disease have been reported among patients with Turner?s syndrome. We present two adult patients with chromosomial disorders (Down?s syndrome, Turner?s syndrome) with Graves? disease without clinical Graves ophthalmopathy. Clinical picture of thyrotoxicosis was oligosymptomatic in the patient with Down?s syndrome, probably because Down?s syndrome represents a syndrome of accelerated ageing. Both were pretreated with antithyroid drugs before radioiodine therapy. Both patients developed postradioiodine hypothyroidism: after 8 months in the case with Turner?s syndrome and after 11 years in the patient with Down?s syndrome. Adults with these two chromosomial disorders should be screened annually for autoimmune thyroid dysfunction.
  • Case Report

    Dursun A, Pala EE, Ugurlu L, Aydin C

    Primary Langerhans Cell Histiocytosis in Thyroid

    Acta Endo (Buc) 2020 16(4): 501-504 doi: 10.4183/aeb.2020.501

    Abstract
    Background. Langerhans cell histiocytosis (LCH) is a rare group of neoplastic diseases resulting from Langerhans dendritic cells. The most common site (80%) is bones. Thyroid gland involvement is exceedingly rare and usually expected to be seen as a part of multisystemic disease. Case Report. We present a 45 year old male patient operated due to multinodular goiter and neck pain, and diagnosed with LCH in his postoperative pathologic examination. As a result of the systemic screening performed after the pathological diagnosis, the disease was interestingly localized to the thyroid gland. Systemic involvement did not develop in the two-year follow-up of the patient who did not receive additional chemotherapy treatment. Conclusion. It is difficult to diagnose LCH in the thyroid gland before surgery. Although surgical treatment with or without chemotherapy is recommended, surgery is not recommended alone since it is generally systemic involvement. However, in primary thyroid LCH cases limited to the thyroid gland, we recommend that only total thyroidectomy treatment should be kept in mind.